Skip to content

Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device

Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03103789
Enrollment
75
Registered
2017-04-06
Start date
2014-04-29
Completion date
2026-08-31
Last updated
2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro Esophageal Reflux

Brief summary

The objective of this study is to design and use a novel, minimally invasive mucosal impedance (MI) technology to inexpensively and accurately test mucosal health in suspected gastroesophageal reflux disease (GERD) and nonerosive reflux disease (NERD) patients as compared to those without GERD.

Detailed description

During routine esophagogastroduodenoscopy (EGD), consented study participants will have the original single channel MI catheter advanced through the working channel of the endoscope. Measurements will be taken at 3 locations for 5 seconds each. The catheter will then be removed and a custom-designed balloon assembly will be inserted through the working channel of the endoscope. The balloon assembly will expand to a maximum diameter of 2 cm spanning from the distal to mid esophagus and contain external metal contacts to form 40 impedance channels made up by 10 axial channels spanning a 10 cm axial area and four radial channels.This design will allow us to measure mucosal impedance both axially and radially thus enabling us to assess the discriminating ability of the device for reflux disease. The balloon assembly will be held in place for 5 seconds. Once the mucosal impedance data have been recorded, the balloon assembly will be deflated and removed by the investigator. The study procedure will add approximately 1-3 minutes of procedure time for each research participant. Those participants who are diagnosed with Grade C or D esophagitis at the initial visit will return for a follow-up visit after treatment with proton pump inhibitor (PPI) therapy to determine whether or not esophagitis has healed as part of their standard of care. If no esophagitis is detected at the follow-up EGD, we will gather one final comparison MI reading during this visit. If esophagitis is still present, follow-up MI will not be performed.

Interventions

DIAGNOSTIC_TESTsingle catheter mucosal impedance testing
DIAGNOSTIC_TESTballoon assembly mucosal impedance testing

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER
Sandhill Scientific
CollaboratorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years

Inclusion criteria

* Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement

Exclusion criteria

* Age less than 18 years old * Patients unable to give informed consent * Use of acid suppressive therapy within last 10 days * Known history of Barrett's esophagus or gastric surgery, other than non-functioning (slipped) Nissen fundoplication

Design outcomes

Primary

MeasureTime frameDescription
mucosal impedance valuesValues will be obtained at conclusion of EGD, an expected average of 6 minutescompare the mucosal impedance values obtained from single channel catheter and balloon assembly catheter in GERD patients and controls

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael Vaezi, MD, PhD

Vanderbilt University Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026